|
WO2003018749A2
(en)
*
|
2001-08-22 |
2003-03-06 |
Shengfeng Li |
Compositions and methods for generating antigen-binding units
|
|
US20030170230A1
(en)
*
|
2002-02-05 |
2003-09-11 |
Caterer Nigel Robert |
Compositions and methods for assembly and stabilization of antibody Fv fragments via antiparallel heterogeneous coiled-coil peptide regions and uses thereof
|
|
US20030157091A1
(en)
*
|
2002-02-14 |
2003-08-21 |
Dyax Corporation |
Multi-functional proteins
|
|
US20040067532A1
(en)
*
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
|
US20050147962A1
(en)
*
|
2002-11-19 |
2005-07-07 |
Wagstrom Christopher R. |
Display of dimeric proteins on phage
|
|
US20050131219A1
(en)
*
|
2003-08-18 |
2005-06-16 |
Urdea Michael S. |
Methods for reducing complexity of a sample using small epitope antibodies
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
JP2007008925A
(ja)
*
|
2005-05-31 |
2007-01-18 |
Canon Inc |
標的物質捕捉分子
|
|
US8299032B2
(en)
*
|
2005-06-27 |
2012-10-30 |
Menicon Co., Ltd. |
Self-assembling peptide and gel produced from the same
|
|
AR056142A1
(es)
*
|
2005-10-21 |
2007-09-19 |
Amgen Inc |
Metodos para generar el anticuerpo igg monovalente
|
|
GB2433506A
(en)
*
|
2005-12-20 |
2007-06-27 |
Sharp Kk |
A method of producing a multimeric capture agent
|
|
GB2433591A
(en)
*
|
2005-12-20 |
2007-06-27 |
Sharp Kk |
Method for functionalising a hydrophobic substrate
|
|
GB2433505A
(en)
*
|
2005-12-20 |
2007-06-27 |
Sharp Kk |
Capture agents for binding a ligand
|
|
WO2008076139A1
(en)
*
|
2006-03-10 |
2008-06-26 |
Tethys Bioscience, Inc. |
Multiplex protein fractionation
|
|
DK1999154T3
(da)
*
|
2006-03-24 |
2012-12-03 |
Merck Patent Gmbh |
Fremstillede heterodimere proteindomæner
|
|
EP4793360A2
(en)
|
2006-03-31 |
2026-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
|
JP5144499B2
(ja)
|
2006-03-31 |
2013-02-13 |
中外製薬株式会社 |
二重特異性抗体を精製するための抗体改変方法
|
|
US7932055B2
(en)
*
|
2006-06-22 |
2011-04-26 |
Novo Nordisk A/S |
Soluble heterodimeric CD94/NKG2 receptors fusion proteins
|
|
WO2007147901A1
(en)
*
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
EP2471816A1
(en)
*
|
2006-08-30 |
2012-07-04 |
Genentech, Inc. |
Multispecific antibodies
|
|
FI120376B
(fi)
*
|
2007-01-17 |
2009-09-30 |
Next Biomed Technologies Nbt O |
Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi
|
|
FI120349B
(fi)
|
2007-03-07 |
2009-09-30 |
Next Biomed Technologies Nbt O |
Menetelmä fuusiopolypeptidin valmistamiseksi
|
|
MX2010000232A
(es)
|
2007-08-21 |
2010-06-02 |
Morphosys Ag |
Metodos mejorados para la formacion de enlaces disulfuro.
|
|
US12529164B2
(en)
|
2007-09-14 |
2026-01-20 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
WO2009036379A2
(en)
|
2007-09-14 |
2009-03-19 |
Adimab, Inc. |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
ES2687808T3
(es)
|
2007-09-26 |
2018-10-29 |
Chugai Seiyaku Kabushiki Kaisha |
Región constante de anticuerpo modificado
|
|
EP3127921A1
(en)
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substition in cdr
|
|
CN104297506B
(zh)
|
2007-10-02 |
2017-05-03 |
赛拉诺斯股份有限公司 |
模块化现场护理装置及其应用
|
|
US8637435B2
(en)
*
|
2007-11-16 |
2014-01-28 |
Merck Sharp & Dohme Corp. |
Eukaryotic cell display systems
|
|
CA2715212A1
(en)
|
2008-03-03 |
2009-09-11 |
Glycofi, Inc. |
Surface display of recombinant proteins in lower eukaryotes
|
|
AR073538A1
(es)
|
2008-09-03 |
2010-11-17 |
Genentech Inc |
Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
|
|
TWI544077B
(zh)
|
2009-03-19 |
2016-08-01 |
中外製藥股份有限公司 |
Antibody constant region change body
|
|
BRPI1014089A2
(pt)
|
2009-04-02 |
2016-04-19 |
Roche Glycart Ag |
anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
|
|
US9067986B2
(en)
|
2009-04-27 |
2015-06-30 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
CN102712696A
(zh)
|
2009-09-16 |
2012-10-03 |
弗·哈夫曼-拉罗切有限公司 |
包含卷曲螺旋和/或系链的蛋白质复合体及其用途
|
|
EP2325311A1
(en)
*
|
2009-11-18 |
2011-05-25 |
Pierre Fabre Medicament |
Novel phage display vector
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
DK2542256T3
(da)
|
2010-03-04 |
2019-08-26 |
Macrogenics Inc |
Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
MX381912B
(es)
|
2010-07-16 |
2025-03-13 |
Adimab Llc |
Colecciones de anticuerpos.
|
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
CN103477197B
(zh)
|
2011-01-21 |
2016-08-17 |
提拉诺斯公司 |
样品使用最大化的系统和方法
|
|
AU2012222833B2
(en)
|
2011-03-03 |
2017-03-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
|
CN103687880B
(zh)
*
|
2011-08-10 |
2016-09-14 |
韩国科学技术院 |
具有增加的脂肪酶活性的两亲性肽-脂肪酶缀合物及其用途
|
|
US8840838B2
(en)
|
2011-09-25 |
2014-09-23 |
Theranos, Inc. |
Centrifuge configurations
|
|
US8475739B2
(en)
|
2011-09-25 |
2013-07-02 |
Theranos, Inc. |
Systems and methods for fluid handling
|
|
US9632102B2
(en)
|
2011-09-25 |
2017-04-25 |
Theranos, Inc. |
Systems and methods for multi-purpose analysis
|
|
US9664702B2
(en)
|
2011-09-25 |
2017-05-30 |
Theranos, Inc. |
Fluid handling apparatus and configurations
|
|
US8435738B2
(en)
|
2011-09-25 |
2013-05-07 |
Theranos, Inc. |
Systems and methods for multi-analysis
|
|
US20140170735A1
(en)
|
2011-09-25 |
2014-06-19 |
Elizabeth A. Holmes |
Systems and methods for multi-analysis
|
|
US9619627B2
(en)
|
2011-09-25 |
2017-04-11 |
Theranos, Inc. |
Systems and methods for collecting and transmitting assay results
|
|
US9268915B2
(en)
|
2011-09-25 |
2016-02-23 |
Theranos, Inc. |
Systems and methods for diagnosis or treatment
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
TWI583699B
(zh)
|
2011-09-23 |
2017-05-21 |
安可美德藥物股份有限公司 |
Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
|
|
US9250229B2
(en)
|
2011-09-25 |
2016-02-02 |
Theranos, Inc. |
Systems and methods for multi-analysis
|
|
US9810704B2
(en)
|
2013-02-18 |
2017-11-07 |
Theranos, Inc. |
Systems and methods for multi-analysis
|
|
US10012664B2
(en)
|
2011-09-25 |
2018-07-03 |
Theranos Ip Company, Llc |
Systems and methods for fluid and component handling
|
|
IN2014CN03887A
(enExample)
*
|
2011-10-27 |
2015-10-16 |
Genmab As |
|
|
BR112014010257A2
(pt)
|
2011-10-31 |
2017-04-18 |
Chugai Pharmaceutical Co Ltd |
molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
|
|
WO2013076580A2
(en)
*
|
2011-11-23 |
2013-05-30 |
Bioven 3 Limited |
Recombinant proteins and their therapeutic uses
|
|
MX2014009565A
(es)
|
2012-02-10 |
2014-11-10 |
Genentech Inc |
Anticuerpos monocatenarios y otros heteromultimeros.
|
|
US9212227B2
(en)
|
2012-04-30 |
2015-12-15 |
Janssen Biotech, Inc. |
ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
|
|
KR20150030744A
(ko)
|
2012-06-27 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
|
|
ES2597228T3
(es)
|
2012-06-27 |
2017-01-17 |
F. Hoffmann-La Roche Ag |
Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
|
|
IN2015DN01115A
(enExample)
|
2012-07-13 |
2015-06-26 |
Zymeworks Inc |
|
|
KR101963231B1
(ko)
*
|
2012-09-11 |
2019-03-28 |
삼성전자주식회사 |
이중특이 항체의 제작을 위한 단백질 복합체 및 이를 이용한 이중특이 항체 제조 방법
|
|
US10329350B2
(en)
*
|
2012-12-26 |
2019-06-25 |
Industrial Technology Research Institute |
Method for producing a multivalent fab fragment with collagen-like peptide
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
|
CA2906566C
(en)
|
2013-03-14 |
2024-09-10 |
Macrogenics, Inc. |
Immunoreactive bispecific molecules at immune effector cells expressing an activation receptor
|
|
CN105358575B
(zh)
|
2013-03-15 |
2020-09-22 |
詹森生物科技公司 |
干扰素α和ω抗体拮抗剂
|
|
CN111366434A
(zh)
|
2013-03-15 |
2020-07-03 |
赛拉诺斯知识产权有限责任公司 |
用于使样品中的细胞破裂的自动化测定装置
|
|
RS57840B1
(sr)
|
2013-03-18 |
2018-12-31 |
Biocerox Prod Bv |
Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
|
|
CN105917235A
(zh)
|
2013-09-06 |
2016-08-31 |
赛拉诺斯股份有限公司 |
用于检测感染性疾病的系统和方法
|
|
US10370776B2
(en)
*
|
2013-09-25 |
2019-08-06 |
Idea Orchard, Llc |
Antibody like protein
|
|
CA2925256C
(en)
|
2013-09-27 |
2023-08-15 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
|
SMT202100473T1
(it)
|
2013-11-06 |
2021-09-14 |
Janssen Biotech Inc |
Anticorpi anti-ccl17
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
PL3099717T3
(pl)
|
2014-01-31 |
2019-10-31 |
Novartis Ag |
Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
CN122399016A
(zh)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
US10647768B2
(en)
|
2014-05-29 |
2020-05-12 |
Macrogenics, Inc. |
Multi-chain polypeptide-containing tri-specific binding molecules
|
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
MX2016017393A
(es)
|
2014-07-01 |
2017-09-05 |
Pfizer |
Diacuerpos heterodimericos biespecificos y sus usos.
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Ｃｄ３３キメラ抗原受容体を使用する癌の処置
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
WO2016019300A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
EP3180359A1
(en)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
|
EP3712171A1
(en)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Treatment of cancer using a cd123 chimeric antigen receptor
|
|
WO2016040294A2
(en)
|
2014-09-09 |
2016-03-17 |
Janssen Biotech, Inc. |
Combination therapies with anti-cd38 antibodies
|
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
EA201790719A1
(ru)
|
2014-09-26 |
2017-07-31 |
Макродженикс, Инк. |
Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
|
|
WO2016054101A1
(en)
|
2014-09-29 |
2016-04-07 |
Duke University |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|
|
SG11201702401RA
(en)
|
2014-10-14 |
2017-04-27 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
PE20171094A1
(es)
|
2014-12-04 |
2017-08-07 |
Janssen Biotech Inc |
Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
|
|
CN107250161A
(zh)
|
2015-01-26 |
2017-10-13 |
宏观基因有限公司 |
包含dr5‑结合结构域的多价分子
|
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
PL3280729T3
(pl)
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CR20170526A
(es)
|
2015-05-20 |
2018-04-03 |
Janssen Biotech Inc |
ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
CN107708734B
(zh)
|
2015-06-22 |
2022-01-11 |
詹森生物科技公司 |
用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
|
|
EP3313441B1
(en)
|
2015-06-24 |
2024-02-21 |
Janssen Biotech, Inc. |
Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
|
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
PE20231958A1
(es)
|
2015-07-30 |
2023-12-06 |
Macrogenics Inc |
Moleculas de union a pd-1 y metodos de uso de las mismas
|
|
MY188405A
(en)
|
2015-08-05 |
2021-12-08 |
Janssen Biotech Inc |
Anti-cd154 antibodies and methods of using them
|
|
JP7027321B2
(ja)
|
2015-11-03 |
2022-03-01 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｃｄ３８抗体の皮下製剤及びその使用
|
|
GB201521393D0
(en)
*
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521383D0
(en)
*
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
|
CN108367069B
(zh)
|
2015-12-14 |
2022-08-23 |
宏观基因有限公司 |
对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
|
|
CN108697794A
(zh)
|
2015-12-17 |
2018-10-23 |
诺华股份有限公司 |
C-met抑制剂和抗pd-1抗体分子的组合及其用途
|
|
KR20180087430A
(ko)
|
2015-12-17 |
2018-08-01 |
얀센 바이오테크 인코포레이티드 |
Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
PT3393504T
(pt)
|
2015-12-22 |
2025-12-30 |
Novartis Ag |
Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
|
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
|
AR108034A1
(es)
|
2016-02-17 |
2018-07-11 |
Macrogenics Inc |
Moléculas de unión a ror1, y métodos de uso de las mismas
|
|
SG11201807489PA
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
EP3431102A4
(en)
|
2016-03-14 |
2019-09-25 |
Chugai Seiyaku Kabushiki Kaisha |
CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
|
|
GB201604458D0
(en)
|
2016-03-16 |
2016-04-27 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against cancers
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
CN109069633A
(zh)
|
2016-04-15 |
2018-12-21 |
宏观基因有限公司 |
新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
|
|
US20230071283A1
(en)
|
2016-04-15 |
2023-03-09 |
Aimee S. Payne |
Compositions and methods for selective protein expression
|
|
AU2017255077B2
(en)
|
2016-04-28 |
2024-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing preparation
|
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
WO2018002181A1
(en)
|
2016-06-28 |
2018-01-04 |
Umc Utrecht Holding B.V. |
TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
|
|
EP3484455A2
(en)
|
2016-07-15 |
2019-05-22 |
Novartis AG |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
KR20230100748A
(ko)
|
2016-07-28 |
2023-07-05 |
노파르티스 아게 |
키메라 항원 수용체 및 pd-1 억제제의 조합 요법
|
|
SG11201900885VA
(en)
|
2016-08-01 |
2019-02-27 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
JP7467117B2
(ja)
|
2016-10-07 |
2024-04-15 |
ノバルティス アーゲー |
癌の治療のためのキメラ抗原受容体
|
|
BR112019012950A2
(pt)
|
2016-12-23 |
2019-11-26 |
Macrogenics, Inc. |
molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo
|
|
KR102607101B1
(ko)
|
2017-01-26 |
2023-11-29 |
제트엘아이피 홀딩 리미티드 |
Cd47 항원 결합 유닛 및 그것의 사용
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
BR112019017628A2
(pt)
|
2017-02-24 |
2020-07-07 |
Macrogenics, Inc. |
molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
|
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
CN106905435B
(zh)
*
|
2017-03-13 |
2020-04-10 |
武汉海沙百得生物技术有限公司 |
一种制备基于蛋白a突变体的结合蛋白的方法
|
|
JP7209298B2
(ja)
|
2017-03-31 |
2023-01-20 |
公立大学法人奈良県立医科大学 |
血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
CN108866635B
(zh)
*
|
2017-05-09 |
2021-11-26 |
安升（上海）医药科技有限公司 |
多特异性蛋白药物及其文库、以及制备方法和应用
|
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
|
MX2019015885A
(es)
|
2017-06-22 |
2020-09-10 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
|
|
CN111050791A
(zh)
|
2017-06-27 |
2020-04-21 |
诺华股份有限公司 |
用于抗tim-3抗体的给药方案及其用途
|
|
SG10201913147WA
(en)
|
2017-07-11 |
2020-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
WO2019018730A1
(en)
|
2017-07-20 |
2019-01-24 |
Novartis Ag |
DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
KR20260090008A
(ko)
|
2017-11-01 |
2026-06-16 |
추가이 세이야쿠 가부시키가이샤 |
생물 활성이 저하된 항체 배리언트 및 아이소폼
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
US11795226B2
(en)
|
2017-12-12 |
2023-10-24 |
Macrogenics, Inc. |
Bispecific CD16-binding molecules and their use in the treatment of disease
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
CN111787949A
(zh)
|
2018-02-15 |
2020-10-16 |
宏观基因有限公司 |
变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
MX2020011844A
(es)
|
2018-05-08 |
2021-04-13 |
Amgen Inc |
Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles.
|
|
WO2019220368A1
(en)
|
2018-05-16 |
2019-11-21 |
Janssen Biotech, Inc. |
Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
CN112384534A
(zh)
|
2018-05-21 |
2021-02-19 |
指南针制药有限责任公司 |
用于增强nk细胞对靶细胞的杀死的组合物和方法
|
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
IL279367B2
(en)
|
2018-06-13 |
2026-05-01 |
Novartis Ag |
BCMA chimeric antigen receptors and their uses
|
|
CA3104295A1
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
JP2021531306A
(ja)
|
2018-07-25 |
2021-11-18 |
アドバンスド アクセラレーター アプリケーションズ エスエー |
神経内分泌腫瘍の処置の方法
|
|
JP7497351B2
(ja)
|
2018-11-13 |
2024-06-10 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
チェックポイント分子に対する多重特異性結合性構築物およびその使用
|
|
KR20210099614A
(ko)
|
2018-12-04 |
2021-08-12 |
노파르티스 아게 |
Cd3에 대한 결합 분자 및 이의 용도
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US20210386763A1
(en)
|
2018-12-20 |
2021-12-16 |
Novartis Ag |
Pharmaceutical combinations
|
|
WO2020136566A1
(en)
|
2018-12-24 |
2020-07-02 |
Sanofi |
Multispecific binding proteins with mutant fab domains
|
|
JP7734075B2
(ja)
|
2018-12-24 |
2025-09-04 |
サノフイ |
疑似ｆａｂベースの多重特異性結合タンパク質
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
JP7579795B2
(ja)
|
2019-02-21 |
2024-11-08 |
マレンゴ・セラピューティクス，インコーポレーテッド |
ＮＫｐ３０に結合する抗体分子およびその使用
|
|
AU2020226893B2
(en)
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
EP3927371A1
(en)
|
2019-02-22 |
2021-12-29 |
Novartis AG |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
PH12021552414A1
(en)
|
2019-03-29 |
2022-07-25 |
Atarga Llc |
Anti fgf23 antibody
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
US12037378B2
(en)
|
2019-05-21 |
2024-07-16 |
Novartis Ag |
Variant CD58 domains and uses thereof
|
|
AU2020279224B2
(en)
|
2019-05-21 |
2024-12-05 |
Novartis Ag |
Trispecific binding molecules against BCMA and uses thereof
|
|
CR20220025A
(es)
|
2019-07-26 |
2022-05-04 |
Janssen Biotech Inc |
Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos
|
|
DE102019121007A1
(de)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Antigenbindende Proteine, die spezifisch an MAGE-A binden
|
|
CN114585651A
(zh)
|
2019-08-08 |
2022-06-03 |
再生元制药公司 |
新型抗原结合分子形式
|
|
TW202120537A
(zh)
|
2019-08-15 |
2021-06-01 |
美商健生生物科技公司 |
用於經改善的單鏈可變片段之材料及方法
|
|
WO2021079195A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Tim-3 inhibitors and uses thereof
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
AU2020379735A1
(en)
|
2019-11-05 |
2022-05-26 |
Regeneron Pharmaceuticals, Inc. |
N-terminal SCFV multispecific binding molecules
|
|
WO2021108661A2
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
IL293978A
(en)
|
2019-12-20 |
2022-08-01 |
Regeneron Pharma |
New il2 agonists and methods of using them
|
|
WO2021138474A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
EP4090335A1
(en)
|
2020-01-17 |
2022-11-23 |
Novartis AG |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
CN115298322A
(zh)
|
2020-01-17 |
2022-11-04 |
贝克顿迪金森公司 |
用于单细胞分泌组学的方法和组合物
|
|
WO2021154839A1
(en)
|
2020-01-30 |
2021-08-05 |
Umoja Biopharma, Inc. |
Bispecific transduction enhancer
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
JP7745556B2
(ja)
|
2020-02-21 |
2025-09-29 |
マクロジェニクス，インコーポレーテッド |
Ｃｄ１３７結合分子及びその使用
|
|
IL295878A
(en)
|
2020-02-27 |
2022-10-01 |
Novartis Ag |
Methods for producing cells expressing a chimeric antigen receptor
|
|
PE20231517A1
(es)
|
2020-03-13 |
2023-09-28 |
Janssen Biotech Inc |
Materiales y metodos para la union de siglec-3/cd33
|
|
WO2021195513A1
(en)
|
2020-03-27 |
2021-09-30 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
|
|
US20230242647A1
(en)
|
2020-05-01 |
2023-08-03 |
Novartis Ag |
Engineered immunoglobulins
|
|
KR20230009430A
(ko)
|
2020-05-12 |
2023-01-17 |
리제너론 파아마슈티컬스, 인크. |
신규 il10 효능제 및 그의 사용 방법
|
|
PE20230389A1
(es)
|
2020-05-27 |
2023-03-06 |
Janssen Biotech Inc |
Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
|
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
WO2022009049A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
US20240279353A1
(en)
|
2020-07-06 |
2024-08-22 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
|
CA3176556A1
(en)
|
2020-07-16 |
2022-01-20 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
JP7862361B2
(ja)
|
2020-07-29 |
2026-05-19 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｈｌａ－ｇ抗原結合ドメインを含むタンパク質及びそれらの使用
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
US20240025992A1
(en)
|
2020-10-22 |
2024-01-25 |
Janssen Biotech, Inc. |
Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
|
|
US20250215081A1
(en)
|
2020-11-06 |
2025-07-03 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
WO2022097065A2
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
KR20230107617A
(ko)
|
2020-11-13 |
2023-07-17 |
노파르티스 아게 |
키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
|
|
CA3202233A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic BioPharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
JP7802303B2
(ja)
*
|
2021-03-01 |
2026-01-20 |
Ｃ４Ｕ株式会社 |
Ｃａｓ３タンパク質を製造する方法
|
|
AR125212A1
(es)
|
2021-03-24 |
2023-06-28 |
Janssen Biotech Inc |
Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas
|
|
AR125210A1
(es)
|
2021-03-24 |
2023-06-21 |
Janssen Biotech Inc |
Anticuerpos dirigidos a cd22 y cd79b
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
BR112023022878A2
(pt)
|
2021-05-04 |
2024-01-23 |
Regeneron Pharma |
Agonistas do receptor fgf21 multiespecíficos e seus usos
|
|
CN117597365A
(zh)
|
2021-05-04 |
2024-02-23 |
再生元制药公司 |
多特异性fgf21受体激动剂及其应用
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2022269451A1
(en)
|
2021-06-22 |
2022-12-29 |
Novartis Ag |
Bispecific antibodies for use in treatment of hidradenitis suppurativa
|
|
AU2022314734A1
(en)
|
2021-07-19 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
CA3229369A1
(en)
|
2021-08-16 |
2023-02-23 |
Regeneron Pharmaceuticals, Inc. |
Novel il27 receptor agonists and methods of use thereof
|
|
KR20240055002A
(ko)
|
2021-09-13 |
2024-04-26 |
얀센 바이오테크 인코포레이티드 |
암 치료를 위한 CD33 x Vδ2 다중특이성 항체
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2023046322A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
|
US20250011428A1
(en)
|
2021-10-28 |
2025-01-09 |
Novartis Ag |
Engineered fc variants
|
|
EP4426437A4
(en)
|
2021-11-03 |
2025-09-17 |
Janssen Biotech Inc |
METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES
|
|
US12559576B2
(en)
|
2021-11-11 |
2026-02-24 |
Regeneron Pharmaceuticals, Inc. |
CD20-PD1 binding molecules and methods of use thereof
|
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
EP4436669A1
(en)
|
2021-11-22 |
2024-10-02 |
Janssen Biotech, Inc. |
Compositions comprising enhanced multispecific binding agents for an immune response
|
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
|
IL316174A
(en)
|
2022-04-26 |
2024-12-01 |
Novartis Ag |
Multiple specific antibodies targeting IL-13 and IL-18
|
|
IL316892A
(en)
|
2022-05-11 |
2025-01-01 |
Regeneron Pharma |
Multispecific proprotein binding molecules and their uses
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
JP2025519158A
(ja)
|
2022-05-27 |
2025-06-24 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
インターロイキン－２プロタンパク質及びその使用
|
|
CN119654338A
(zh)
|
2022-06-04 |
2025-03-18 |
再生元制药公司 |
白细胞介素-2蛋白质原及其用途
|
|
CA3263767A1
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND PROCESSES ALLOWING CROSSING THE BLOOD-BRAIN BARRIER
|
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
|
KR20250048583A
(ko)
|
2022-08-18 |
2025-04-09 |
리제너론 파아마슈티컬스, 인크. |
인터페론 전구단백질 및 이의 용도
|
|
IL320562A
(en)
|
2022-11-02 |
2025-07-01 |
Janssen Biotech Inc |
Cancer treatment methods
|
|
US20260209385A1
(en)
*
|
2022-12-08 |
2026-07-23 |
Analytical Biosciences Shanghai Limited |
Bispecific/multi-specific antibodies and uses thereof
|
|
JP2026500017A
(ja)
|
2022-12-16 |
2026-01-05 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ａａｖ粒子に結合する抗原結合分子及びその使用
|
|
EP4638729A1
(en)
|
2022-12-23 |
2025-10-29 |
Regeneron Pharmaceuticals, Inc. |
Ace2 fusion proteins and uses thereof
|
|
AU2024207005A1
(en)
|
2023-01-13 |
2025-08-28 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
CN121002062A
(zh)
|
2023-01-13 |
2025-11-21 |
再生元制药公司 |
Fgfr3结合分子及其使用方法
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
CN121057744A
(zh)
|
2023-02-28 |
2025-12-02 |
再生元制药公司 |
多价抗刺突蛋白结合分子及其用途
|
|
IL322890A
(en)
|
2023-02-28 |
2025-10-01 |
Regeneron Pharma |
Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
|
|
WO2024233926A1
(en)
|
2023-05-10 |
2024-11-14 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
KR20260026098A
(ko)
|
2023-05-12 |
2026-02-25 |
리제너론 파아마슈티컬스, 인크. |
인터페론 수용체 길항제 및 이의 용도
|
|
CN121646605A
(zh)
|
2023-06-11 |
2026-03-10 |
再生元制药公司 |
环化抗体分子
|
|
IL326398A
(en)
|
2023-08-07 |
2026-04-01 |
Janssen Biotech Inc |
Gucy2c antibodies and uses thereof
|
|
WO2025042428A1
(en)
|
2023-08-18 |
2025-02-27 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules and uses thereof
|
|
WO2025068957A1
(en)
|
2023-09-29 |
2025-04-03 |
Novartis Ag |
Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations
|
|
KR20260113057A
(ko)
|
2023-11-14 |
2026-07-21 |
리제너론 파아마슈티컬스, 인크. |
조작된 중쇄 가변 도메인 및 이의 용도
|
|
WO2025122614A1
(en)
|
2023-12-05 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Il18 receptor agonists and methods of use thereof
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025133340A1
(en)
*
|
2023-12-21 |
2025-06-26 |
Ludwig Institute For Cancer Research Ltd |
Heterodimeric proteins comprising dimerization motifs and methods of using
|
|
WO2025199243A1
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Trivalent multispecific binding molecules and methods of use thereof
|
|
US20260041768A1
(en)
|
2024-05-03 |
2026-02-12 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma with car-t cells and bispecific antibodies
|
|
WO2025231372A2
(en)
|
2024-05-03 |
2025-11-06 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma with car-t cells and bispecific antibodies
|
|
WO2025240335A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
US20250361309A1
(en)
|
2024-05-24 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il12 receptor agonists
|
|
WO2025255480A1
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Tetravalent multispecific binding molecules and methods of use thereof
|
|
WO2025255452A2
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses thereof
|
|
US20260055171A1
(en)
|
2024-06-11 |
2026-02-26 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonists and methods of use thereof
|
|
WO2026025058A1
(en)
|
2024-07-25 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Aav viral particles retargeted to egfr-expressing cancer cells
|
|
WO2026036047A1
(en)
|
2024-08-08 |
2026-02-12 |
Altus Enterprises, Inc. |
Antibody molecules to fixa and fx and uses thereof
|
|
WO2026039791A1
(en)
|
2024-08-16 |
2026-02-19 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il2 receptor agonists
|
|
US20260167709A1
(en)
|
2024-09-11 |
2026-06-18 |
Novartis Ag |
Antibodies targeting il-31
|
|
WO2026076013A1
(en)
|
2024-10-01 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted il2 receptor agonists and multispecific t-cell engagers
|
|
WO2026075989A1
(en)
|
2024-10-01 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Engineered igg molecules and methods of use thereof
|
|
WO2026102093A1
(en)
|
2024-11-07 |
2026-05-15 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2026136279A1
(en)
|
2024-12-16 |
2026-06-25 |
Regeneron Pharmaceuticals, Inc. |
Engineered single domain antibody constructs and methods of use thereof
|
|
WO2026151679A1
(en)
|
2025-01-07 |
2026-07-16 |
Compass Therapeutics, Llc. |
Multispecific binding constructs targeting pd-1 and vegf and uses thereof
|